PT  - JOURNAL ARTICLE
AU  - Elham Ouspid
AU  - Nazanin Razazian
AU  - Abdorreza N. Moghadasi
AU  - Nasrin Moradian
AU  - Daryoush Afshari
AU  - Arash Bostani
AU  - Payam Sariaslani
AU  - Atefeh Ansarian
TI  - Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
AID  - 10.17712/nsj.2018.2.20170434
DP  - 2018 Apr 01
TA  - Neurosciences Journal
PG  - 129--134
VI  - 23
IP  - 2
4099  - http://nsj.org.sa/content/23/2/129.short
4100  - http://nsj.org.sa/content/23/2/129.full
SO  - Neurosciences (Riyadh)2018 Apr 01; 23
AB  - Objectives: To investigate the clinical effectiveness and safety of fingolimod in the western Iranian population.Methods: This study was performed as a prospective observational study between March 2014 and October 2015. Sixty patients with relapsing remitting multiple sclerosis (RRMS) who were referred to the MS clinic of Imam Reza Hospital, which is affiliated with Kermanshah University of Medical Sciences, Iran, were treated with 0.5 mg oral fingolimod capsules once daily for 12 months. The outcomes were clinical and included the annualized relapse rate, expanded disability status scale (EDSS) change, proportion of relapse-free patient, and side effects.Results: An 85% reduction in the annualized relapse rate compared with the baseline (from 1.8±1.35 to 0.27±0.58, p=0.001) was observed, and 76.66% of patients were free from relapse after the 12-month intervention. In addition, a significant reduction of EDSS was measured from 3.32 at baseline to 2.97 (p=0.001). The overall adverse events in our study were similar to those in previous studies.Conclusion: The present study confirms the effectiveness of fingolimod as a second-line therapy in western Iranian RRMS patients. Fingolimod side effects were generally mild and tolerable.